Pangenia's News Updates

2020.09.01

Pangenia launches PanTEST COVID-19 and the latest speical offer

Due to the recent outbreak of the 3rd wave of COVID-19, our PanTEST can give you and your family members extra assurance on safety against infection. We recommend you and your family members to take the test as soon as possible to get informed of your present immune status and your risk exposure. Those with chronic diseases (e.g. obesity, diabetes, hypertension, etc.) that are at a high fatality rate upon COVID-19 infection may benefit from taking our PanTEST as early detection and immediate medical actions may save you and your family. Our company provides the following tests,

1. Deep Throat Saliva Test

  • Dual Verification Technology

*** Pangenia Lifesciences Limited has participated in the SARS-CoV-2 Quality Assurance Program offered by the Hong Kong Centre for Health Protection (CHP)  and  Quality Control for Molecular Diagnostics (QCMD), accredited by United Kingdom Accreditation Service (UKAS) which we passed with a concordance of 100% against intended results. Our PanTEST (RT-PCR test for SARS-CoV-2) results in these programs demonstrated our laboratory’s competency in performing the SARS-CoV-2 viral detection with the highest accuracy ***

2. Blood Antibody Test

  • Approved by the US Food and Drug Administration (FDA) and Public Health England (UKNHS)
  • 99.9% Sensitivity
  • Up to 99.8% Specificity

Special Offer:

1.Individual Test (CVP) - CLICK HERE TO BUY

2.Welcome to make an APPOINTMENT and INQUIRIES for other Tests (CV1, CV2, & CVA) · HOTLINE 3989 6160

 

*** We provide Comprehensive, Secure and Professional Services ***

 

Precautions

  • The company reserves the right to modify the services at any time without prior notice

 

Frequently Asked Questions about COVID-19 Testing:

 

Q1: What is the difference between deep throat saliva nucleic acid test and blood antibody test?

A1: Nucleic acid test (RT-PCR) can detect whether there is COVID-19 virus in deep throat saliva, and blood antibody test whether COVID-19 antibodies exist in the blood.

 

Q2: Why deep throat saliva or sputum is used for the PanTEST COVID-19 RT-PCR?

A2: For the nasopharyngeal or throat swab collection, the process should be handled by trained professionals. And yet, the process can induce coughing and sneezing, which generates aerosol that increases the risk of viral transmission. In contrast, saliva/sputum has been proposed as an alternative specimen that is less invasive and could be collected by the patients themselves.

 

Q3: Is there any difference in term of analytical sensitivity between deep throat saliva/sputum and nasopharyngeal swab? 

A3: Accordingly to several reports1–4, under standardized procedures, there is no significant difference in nucleic acid detection using these two types of specimens. Recently, Yale University published a set of data in The New England Journal of Medicine to support the feasibility of deep throat saliva as a test specimen.

 

Q4: Why does PANGENIA recommend doing the PanTEST deep throat saliva RT-PCR test (CV1, CV2 & CVP)?

A4: Pangenia Lifesciences Limited has participated in the SARS-CoV-2 Quality Assurance Program offered by the Hong Kong Centre for Health Protection (CHP) and Quality Control for Molecular Diagnostics (QCMD, accredited by United Kingdom Accreditation Service (UKAS)) which we passed with a concordance of 100% against intended results. Our PanTEST (RT-PCR test for SARS-CoV-2) results in these programs demonstrated our laboratory’s competency in performing the SARS-CoV-2 viral detection with the highest accuracy.

 

Q5: What is PANGENIA Dual Verification Technology?

A5: In general, many laboratories in the market will only perform a nucleic acid test on each sample. In order to improve the accuracy and reliability of the test results, PANGENIA adopts Dual Verification Technology. Two technologies are used for testing on each sample, and the results are more accurate, which makes everyone more at ease.

 

Q6: What is the PANGENIA COVID-19 blood antibody test?

A6: PANGENIA uses the most advanced and highly sensitive ECLIA detection method to detect COVID-19 blood antibodies, which is more accurate, comparing with ELISA detection methods and rapid antibody detection kits commonly used in the market. This ECLIA detection method is widely used in the United Kingdom and the United States, and has been certified by the US Food and Drug Administration (FDA EUA) and the European Union (CE), with an accuracy of more than 99.9%.

 

Q7: Why does PANGENIA recommend doing the PanTEST antibody test (CV1 & CVA)?

A7: PANGENIA is one of the few qualified medical laboratories in the market which could provide blood antibody test. The test is capable of detecting past exposures to the COVID-19 virus. Recently COVID-19 carrier cases had been reported in Hong Kong implicating that there may be more hidden asymptomatic carriers within the territory (the 1.5-year-old boy and his mother were found to have recovered from the viral infection naturally while both were asymptomatic and with no record of travelling abroad). Our PanTEST antibody test can give you and your family members extra assurance on safety against infection. We recommend you and your family members to take the test as soon as possible to get informed of your present immune status and your risk exposure. Those with chronic diseases (e.g. obesity, diabetes, hypertension, etc.) that are at a high fatality rate upon COVID-19 infection may benefit from taking our PanTEST antibody test as early detection and immediate medical actions may save you and your family.

 

Q8: Why we offer both deep throat saliva nucleic acid test and blood antibody test?

A8: The deep throat saliva nucleic acid test can detect whether there is COVID-19 infection currently, while the blood antibody test can detect the presence of antibodies in the body. If the result of blood antibody test is "positive," it means that the tester can be either currently infected or previously infected with COVID-19. People who have been in close contact with the person even if RT-PCR result is negative should also be tested as soon as possible.

 

                        Illustrative figure of the immune responses upon SARS-CoV-2 infection

 

Source: Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (COVID-19) by the numbers. Elife. 2020;9:e57309. Published 2020 Apr 2. doi:10.7554/eLife.57309


Q9: Why does PANGENIA recommend to do nucleic acid tests at least twice?

A9: The "incubation period" refers to the time between infection and the appearance of clinical symptoms. The current estimates for the "incubation period" of COVID-19 are mostly 1 to 14 days, average about 5 days. During the early incubation period, the patient may has very low levels of virus. There is a chance that the virus cannot be detected and a "false negative" result may occur. In order to avoid a "false negative" result, we will provide two deep throat saliva nucleic acid tests at different time to double check.

 

Q10: If the second deep throat saliva nucleic acid test result is negative, do I need to continue the test in the future?

A10: Since COVID-19 epidemic is still not under control, we highly recommended that you should repeat the deep throat saliva nucleic acid test at regular interval.      

     

Q11: Do I need to make an appointment for the test?

A11: Advance booking is required.

 

Q12: How long does it take to get the test result?

A12: The testing results will be sent via email within 24-48 hours after submitting the sample.

 

Reference

1.The New England Journal of Medicine, 2020, DOI: 10.1056/NEJMc2016359

2.Leung, E.C., et al., Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2. J Med Virol, 2020.

3.To, K.K., et al., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis, 2020. 20(5): p. 565-574.

4.To, K.K., et al., Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis, 2020. 71(15): p. 841-843.